With the exception of two studies (Attar et al. [36], Ghaznawie et al. [39]), which included patients with cancers other than breast cancer (though in both studies, over 65% of the patients had breast cancer), all remaining studies focused exclusively on breast cancer patients, including both HER2-positive and HER2-negative cases. Here, ERBB2 is linked to breast carcinoma.